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Background–objective: Prevalence data of cognitive impairment in Schizophrenia based on large population
samples are scarce. Our goal is to relate cognition and functional outcomes, and estimate prevalence of cognitive
impairment in a large sample of schizophrenia outpatients treated with second-generation antipsychotics.
Method:A cross-sectional outpatient evaluation conducted during follow-up visits. Selection criteria included six-
months stable treatment. The brief battery, EPICOG-SCH, covered four cognitive domains related to functional
outcomes: working memory (WAIS-III-Letter-Number-Sequencing), executive function (Category Fluency Test;
CFT), verbal memory (WMS-III-Logical-Memory), and information processing speed (Digit-Symbol-Coding and
CFT). Clinical severity and functional impairment were assessed with CGI-SCH and WHO DAS-S. Impairment
prevalence was calculated at ≤1.5 SD.
Results: Among patients recruited (n = 848) in 234 participating centers, 672 were under 6-month treatment.
61.5% (n= 413) reported cognitive impairment according to CGI-SCH Cognitive Subscale. Estimated prevalences
were 85.9% (95% CI 85.6–86.2%) CFT-Fruits; 68.3% (95% CI 67.8–68.8%) CFT-Animals; 38.1% (95% CI 37.5–38.3%)
Digit-Symbol-Coding; 24.8% (95% CI 24.1–25.5%) Verbal Memory-Units; 20.9% (95% CI 20.2–21.6%) Letter-
Number Sequencing; 11.7% (95% CI 11.0–12.4%) VerbalMemory-Items. Negative and Depressive symptoms, Def-
icit Syndrome, and functional disability were related to poor performance. Functional disability was predicted by
CGI-SCH-Overall severity (OR = 1.34635, p b 0.0001), CGI-SCH-Negative Symptoms (OR = 0.75540,
p b 0.0001), working memory (Letter-Number-Sequencing) (OR = −0.16442, p = 0.0004) and the time-
course (OR = 0.05083, p = 0.0094), explaining 47% of the observed variability.
Conclusion: Most prevalent impairments were on executive function and processing speed domains; however,
working memory showed the strongest relationship to functional disability. Monitoring cognitive function during
follow up is critical to understand patient’s everyday functional capacity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the primary features of schizophrenia is cognitive impairment;
in past decades, this has been associated with patient functioning in daily
life (Bowie andHarvey, 2006; Bowie et al., 2008; Green, 1996; Green et al.,
2000, 2004a; Velligan et al., 1997;Harvey et al., 2006a,b) and greatly inﬂu-
ences functional outcome on nearly the same level as negative symptoms
(Hofer et al., 2005). Although the characteristics of cognitive impairment
of schizophrenia have been extensively described, there arewide variabil-
ity and heterogeneity in the domains that are affected and their degree ofiatria, Facultat de Medicina,
laterra, s/n-08193 Bellaterra,
Domingo), bobes@uniovi.es
a).
Inc. This is an open access article uninvolvement (Fioravanti et al., 2012). A large proportion of schizophrenia
patients – but not all –may develop signiﬁcant, moderate-to-severe cog-
nitive impairment (Montgomery and van Zwieten-Boot, 2007), but also it
has been reported that 20–25% of patients may have normal scores on
neuropsychological tests (Palmer et al., 2009; Wexler et al., 2009).
Existing studies on cognitive deﬁcits, have focused primarily on two
methods of comparison: most studies compared patients’ deﬁcits with
deﬁcits in control groups, while other have compared patients’ cognitive
performance to that of the general population using normative data
(Keefe et al., 2006). In one of the ﬁrst published meta-analyses, the aver-
agepatient performance on22psychological testswas described to bebe-
tween 0.46 and 1.41 standard deviations below controls (Heinrichs and
Zakzanis, 1998), and later on it was showed that deﬁcit severity can be
as great as 2–3 standard deviations below the mean (Keefe et al., 2006).
Drug therapy also plays a role in the patient’s cognitive health, and
cognitive symptoms’ responses following treatment with second-der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2006a; Keefe et al., 1999). Contrary towhat onemight expect, interna-
tional surveys on the use of neuropsychological assessments in psy-
chiatric clinical practice have shown that cognitive assessment is not
usually included in routine clinical practice (Belgaied et al., 2014;
Green et al., 2005).
Schizophrenia’s characteristic cognitive deﬁcits have led to vari-
ous attempts to generate speciﬁc batteries (Gold et al., 1999; Hurford
et al., 2011; Keefe et al., 2004; Nuechterlein et al., 2008; Pietrzak et al.,
2009; Velligan et al., 2004) (for a review of the available measure-
ment tools, see Fagerlund, 2004 and Pino et al, 2008) (Pino et al.,
2008), some of which aim to meet time constraints of clinical settings
and also result in a composite score representative of the overall deﬁcit.
Also, the NIH initiative, Measurement and Treatment Research to Im-
prove Cognition in Schizophrenia (MATRICS), promoted cognitive as-
sessment in pharmacological research on schizophrenia, following a
pre-deﬁnedmethodology aiming to build a battery addressed to specif-
ic goals (Buchanan et al., 2005; Green et al., 2004a; Green and
Nuechterlein, 2004).
In clinical practice, determining patient’s cognitive abilities con-
veys speciﬁc challenges i.e. not only the efﬁciency to initially deﬁne
the existence and degree of impairment and to estimate patients’
cognitive strengths andweaknesses, but also to predict its related im-
pact on clinical and functional outcomes, tomonitor the effect of clin-
ical changes on cognition and to determine the effect of adjustments/
changes on drug treatments (Fagerlund, 2004) or the impact of reha-
bilitation programs.
After decades of research, the relationship between cognition and
function in schizophrenia is now well recognized but not fully de-
scribed; little is known about this interrelationship over time, about
how other variables may inﬂuence the role of cognition in shaping
functional outcomes (Rajji et al., 2014) or how changes induced in
patients’ cognitive functioning impact on functional outcomes
(Green and Nuechterlein, 2004; Matza et al., 2006; Ventura et al.,
2013).
In this Epidemiological Study of Cognitive Impairment in Schizo-
phrenia (EPICOG-SCH) we evaluated the performance of patients on
speciﬁc cognitivedomains associatedwithpatients’ functional status ac-
cording to review works published elsewhere, and we estimated the
prevalence of cognitive impairment in those domains using published
normative data.
This study is based on a large sample of clinically stable schizo-
phrenia outpatients treated with second-generation antipsychotic
drugs as their primary therapy. To this end, the EPICOG-SCH brief bat-
tery was built using cognitive tests validated in Spain and with avail-
able normative data from the general population. In addition, we
aimed to describe the observed relationship between cognitive, clini-
cal variables and patients’ functional disability. Functional disability
was assessed by the World Health Organization Short Disability As-
sessment Schedule (WHO DAS-S) (Janca et al., 1996) in which clini-
cians assesses the patient’s difﬁculties in different functional areas
due to his or her mental illness.
This study will provide useful information for clinicians to better
understand the complex interaction between cognitive, clinical and
functional factors in stable schizophrenia outpatient and, as well as,
will provide reference data on the prevalence of cognitive impair-
ment based on a large population, as reference for future studies.
2. Materials and methods
We conducted a cross-sectional epidemiological study with a
sample of schizophrenia outpatients on maintenance treatment
with second-generation antipsychotic drugs. The patients visited a
clinic for a routine control visit at one of the community-basedmental-health service centers in Spain, within of the National Public
Health System including all 17 Autonomous Communities in the
country.
2.1. Participants
Inclusion criteriawere at least 18 years of age, having an established
diagnosis of schizophrenia according to DSM-IV-TR criteria (American
Psychiatric Association, 2002), on maintenance treatment with at least
one second-generation antipsychotic drug and treatment remaining
stable during the previous sixmonths, and completion of informed con-
sent to participate in the study. Exclusion criteria were not having a
clinical history of at least one year at the participating center, suffering
an acute depressive episode at the time of selection, at least 2 months
elapsed since the most recent neuropsychological or cognitive assess-
ment and presenting severe or uncorrected auditory or visual sensory
dysfunctions or psychomotor disturbances that would prevent the
completion of cognitive tasks.
The study was approved by the Clinical Research Ethics Commit-
tee of one of the participating centers, and this approval extended
to all the other participating centers in the country.
2.2. Cognitive assessment battery
For the selection of the domains to be included, theMATRICS-RAND
review work was taken into account regarding documented relation-
ship of subtests to functional outcomes (Nuechterlein et al., 2008;
Green et al., 2004b). Subtests were selected also considering available
versions validated at local level and with published local normative
data based on general population. Four domains were identiﬁed as rel-
evant in schizophrenia including executive function (althoughnot con-
sidered initially within the MATRICS reviewmodel); the selected tests
composing the ﬁnal EPICOG-SCH battery were; Letter-Number Se-
quencing (WAIS-III) (Weschler, 2001;Gold et al., 1997) (workingmem-
ory), Logical Memory (WMS-III-Text A) (Weschler, 2001) (verbal
memory), Category Fluency Test (3 categories: animals, fruits, cities–
villages) (Benton andHamscher, 1978) (executive functioning and infor-
mation processing speed), and Digit-Symbol Coding (WAIS-III)
(Weschler, 2001) (information processing speed). For Category Fluency
Test the category “vegetables” was substituted by “cities–villages” due
to issues observed in Spanish languages with the original one
(Pascual et al., 2000; Buriel et al., 2004). Category Fluency Test was se-
lected as measure of executive function as described widely in the liter-
ature (Lezack et al., 2004; Heilman and Valenstein, 2003) but also as a
measure of information processing speed.
2.3. Procedure
Data were collected from a clinical patient interview, including
sociodemographic and clinical data and details about both antipsy-
chotic treatments and other concomitant treatments, especially
treatments using anticholinergic agents. In addition, socio-
occupational status, functional status in different aspects of life and
a history of cognitive difﬁculties symptoms were assessed.
Data on the clinical psychiatric diagnosis included the date of the
ﬁrst schizophrenic episode and the type of schizophrenia according
to the DSM-IV-TR (American Psychiatric Association, 2002). The
presence of the Deﬁcit Syndrome was recorded (Kirkpatrick et al.,
2000; Arango et al., 1998, 2004), and the severity of the disorder
was determined based on the week before the visit by the Clinical
Global Impression-Schizophrenia (CGI-SCH) Severity Scale (Haro
et al., 2003a,b) which includes aspects of the disease in addition to
overall severity, such as positive, negative, depressive and cognitive
symptoms.
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Socio-occupational information about the patients’ competitive
employment working activity was recorded (Knudsen et al., 2000).
The impact of the patient’s overall mental health on daily function
was assessed using the WHO DAS-S (Janca et al., 1996; Sartorius
et al., 1986). This assessment tool is a semi-structured interview de-
signed to assess disability frommental disorders and includes the fol-
lowing dimensions: personal care, occupational and family functioning,
functioning in the wider social context and an overall score.
2.3.2. Cognitive test
Before administering the battery, patients were asked about the
existence of cognitive difﬁculties using an open question and asking
about previously conducted testing. Cognitive battery was composed
of four subtests with an estimated mean administration time be-
tween 20 and 30 min; the sequence of administration was set in
theway to avoid administering consecutively tests with verbal mate-
rial stimuli. Investigators were selected provided they had demon-
strable experience administering cognitive tests. Procedures to
administer the battery were standardized using the instructions pro-
vided in the relevant manuals (Buriel et al., 2004; Wechsler, 2001;
Weschler, 2001). Raters were asked to register all patients’ responses
into the forms and to obtain subtest scores.
2.4. Data analysis
All forms were centrally collected and scores for cognitive tests
were centrally monitored to check accuracy and consistency among
raters. After reviewing cognitive tests of 40% of the patients, observed
discrepancies on scoring criteriawere discussed in ameeting to reach
consensus. Discrepancies were foundmainly on the Category Fluency
tests in the way raters scored language/country speciﬁcities on the
produced names and also on Logical Memory when accepting syno-
nyms as correct answers, among others. Resolution criteria were
then applied to all data. Raw scores were transformed into standard-
ized scores (scalar or centile depending on the test) based on pub-
lished local normative data (Buriel et al., 2004; Wechsler, 2001;
Weschler, 2001). For standardization age was the only stratiﬁcation
variable that was available for all age ranges for all subtests with
the exception of Category Fluency Cities–Villages. For the WHO-
DAS-S, the sum of the scores was considered the measure of overall
patient functional disability.
Disability based on the cognitive tests results was identiﬁed as
equal to or less than 1.5 standard deviations (SD) from the mean of
standardized scores (i.e., a 1.5 SD cut-off or 10th centile)
i.e., corresponding to a score b5.5 for scalar ratings and b10 for
centiles. The prevalence of impairment was deﬁned as the percentage
of patients with scores below the cut-off mentioned; prevalence esti-
mates are givenwith the 95%CI. Rawand adjustedprevalence, accord-
ing to the estimated total number of patients with schizophrenia in
Spain, was estimated. For adjusted prevalence, weights were derived
from 2004 population data provided by the National Statistics Insti-
tute (Instituto Nacional de Estadística, 2006) and considering a preva-
lence of schizophrenia of a constant 1% in all constituted communities.
In addition, we also provided the prevalence estimates for the cut-off
of 1.0 and 2.0 SD below the mean, corresponding to the lower limit of
normal cognitive performance and to severe impairment, respectively
(Harvey et al., 2006a; Taylor and Heaton, 2001); these cut-offs corre-
spond to scores between b7 and b4 for scalar scores and between b25
and b5 for centile scores, respectively. The prevalence of impairment
for each domainwas establishedwhen all of the tests administered as-
sociated with that domain were below the cut-off. Criterion validity of
the battery was based on its relationship with actual patient’s clinical
and functional status. Wilcoxon test was used to describe differenceson performance among clinical subgroups; Spearman correlations
were used to describe the association between cognitive performance
and, clinical severity and functional disability results.
For exploratory purposes, we constructed two regression models
to study the association between cognitive performance and the
overall level of functional disability. Both the scores (raw and stan-
dardized) of all of the tests and the clinical variables were considered.
All of the statistical tests were performed with the signiﬁcance level
set at 5%. The data were analyzed using SAS software release 8.02
(SAS Institute, Cary, NC).
3. Results
3.1. Description of patients and subgroups
Eight hundred and forty-eight (848) patients from 234 centers
were evaluated between June and December 2006, from which 176
cases with protocol deviations were observed (20.8%) primarily due
to an insufﬁcient duration of maintenance treatment or due to docu-
mented changes on the prescribed drugs within the period or not
enough data to conﬁrm treatment duration. Ultimately, 672
patients with no changes on their drug therapy regimenwere includ-
ed in the group of analyzed patients. Table 1 shows the patients’
sociodemographic and clinical characteristics. The sample consisted
of patients with mild to moderate degrees of disease severity
according to the CGI-SCH scale (Haro et al., 2003a,b) showing a
wide variability in disease duration and overall adherent to pre-
scribed drug treatment. Occupationally active patients comprised
18.9% (n = 122) of the cases; 33.6% (n = 226) had some type of
government-recognized disability. Table 1 shows the results obtained
in each functional area evaluated by the WHO-DAS-S; the mean of
overall disability was 8 out of 20, with greater disability observed in
the subscales of occupational functioning and functioning in the wider
social context.
A total of 67.4% of patients (n=453)met the criteria for the Deﬁcit
Syndrome (Arango et al., 1998; Kirkpatrick et al., 2000) and 64.3% (n=
429) showed some degree of depression according to the CGI-SCH
scale (Haro et al., 2003a,b). Nine hundred and forty-six antipsychotic
treatmentswere recorded, either as primary or as secondary treatment
for schizophrenia, and 15.6% of patients had prescribed anticholinergic
agents as concomitant treatment (n= 105). In total, 42.6% (n= 286
cases) were being treated simultaneously with several antipsychotic
agents. Among the registered treatments there were Amisulpride
(40.8%, n = 274), Risperidone (35.7%, n = 240), Olanzapine (22.9%,
n = 154) and Quetiapine (11.8%, n= 79), and other agents at lower
percentages.
A few patients had a previous cognitive assessment (12.5%, n =
83 cases), with amean time of 28.5months from the previous test. Ac-
cording to clinical criteria, a large number of patients had cognitive im-
pairment (CGI-SCH ≥ 2 minimal = 91.2%, n = 613; and CGI-SCH ≥ 3
moderate = 61.5%, n = 413). Additionally, in response to the open
question, most patients reported having or suffering cognitive difﬁcul-
ties in their daily lives (78%, n=524), including difﬁculties in concen-
tration, remembering, maintaining attention when reading, planning
capacity, keeping on track during conversations, following instructions
or a combination of these, among others.
3.2. Performance and cognitive impairment
The domainswith the lowest results were executive function (Cat-
egory Fluency Test) and information processing speed (Digit-Symbol
Coding and Category Fluency Test), whereas the best resultswere ob-
tained in the verbal memory domain, speciﬁcally, in the immediate
recall of items (see Table 2).
Table 1
Sociodemographic, clinical and functional characteristics of the patients.
Variable Total Sample
(N = 672)
Mean SD
Age (years) 39.0 10.5
Time course of the disorder (years) 14.4 9.9
n %
Schizophrenia subtypes
Paranoid (295.30) 500 75.3
Undifferentiated (295.90) 71 10.7
Residual (295.60) 59 8.9
Disorganized (295.10) 32 4.8
Catatonic (295.90) 2 0.3
Gender
Man 447 67.2
Woman 218 32.8
Educational level completed
No education completed 66 9.8
Primary 312 46.4
High School 226 33.6
University 60 8.9
Unknown 8 1.2
Psychiatric Comorbiditiesa
Substance Use 165 24.6
Mood disorders 74 11.1
Anxiety disorders 51 7.6
Personality disorders 28 4.2
Family Historyb
Depressive disorder 171 25.5
Psychotic disorder 133 19.6
Substance abuse 94 14.0
Bipolar Disorder 23 3.4
Treatment Adherence
Yes 542 80.7
No 103 15.3
Mean SD
Mental Health Care Records (Past Year)
Number visits to the specialist 7.6 5.9
Number relapsesc 0.7 2.5
Elapsed time since last relapse (months) 25.5 33.9
Number of hospital admissionsc 0.4 1.1
Mean length of hospital admissions (days) 6.5 13.7
n %
Governmental disability/handicap
Ofﬁcially awarded 226 33.6
Mean SD
Percentage of disability acknowledged (%)d 64.4 10.9
n %
Patients with long term labor incapacity (disability awarded ofﬁcially)
Temporal labor incapacity 26 3.9
Permanent labor incapacity 338 50.3
Absolute (for any type of work) 197 62.3
Total (for the usual activity) 101 32.0
Partial 17 5.4
Great incapacity 1 0.3
Under evaluation 52 7.7
Unknown 86 31.1
Occupational status each
Retired 241 35.6
Unemployed 176 26.2
Active work 122 18.9
Housework 48 7.2
Student 34 5.1
Unknown 51 3.4
Type of work
Not working or unknown 472 70.2
(continued on next page)
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Table 1 (continued)
Variable Total Sample
(N = 672)
Mean SD
Worker in a factory 81 12.5
Qualiﬁed worker 44 6.5
Services/Retails 40 6.0
Secretary/Receptionist 10 1.5
Associated professional 9 1.3
Professional 12 1.8
Manager-Business Administrator 4 0.6
Currently studying 80 11.9
Principal income source
Pension-subsidy 264 39.3
Family support 139 20.7
Salary or unemployement beneﬁt 134 19.9
Various income sources 43 6.4
Not speciﬁed 58 8.6
Social interaction: frequency of interaction with family
On a daily basis or almost daily 267 39.7
Once or twice per week 140 20.8
Once or twice per month 119 17.7
Every several month 64 9.5
Rarely 65 9.7
Never 10 1.5
Unknown 7 1.0
Social interaction: frequency of interaction with friends
On a daily basis or almost daily 252 37.5
Once or twice per week 201 29.9
Once or twice per month 83 12.4
Every several month 20 3.0
Rarely 78 11.6
Never 26 3.9
Unknown 12 1.8
Mean SD
WHO DAS-Se
Total Score 8.0 4,1
Personal Care 1.1 1.1
Occupational Functioning 2.5 1.4
Familiar Functioning 1.9 1.2
Broad Social Context Functioning 2.6 1.3
WHO DAS-S, World Health Organization Disability Scale-Short Version (Janca et al., 1996; Sartorius et al., 1986).
WHO-DAS-S subscales also showed associationwith their corresponding registered sociodemographic data. In thiswayOccupational functioningwas related to patient’s actualWork
Status (Chi2 = 172.7626, gl = 25, p b 0.0001) and Principal Source of Incomes (Chi2 = 164.9863, gl = 20, p b 0.0001). Broad social context functioningwas associated both with
Frequency of Social Interactions with Family (Chi2 = 84.6947, gl = 25, p b 0.0001) and with Friends (Chi2 = 218.8328, gl = 25, p b 0.0001). Familiar Functioningwas associated
to Frequency of Social Interaction with Family (Chi2 = 73.2496, gl = 25, p b 0.0001). No complementary information was recorded to analyze the association to Personal Care
subscale.
a Psychiatric conditions were reported in 45.5% (n = 305) of the patients as associated to the diagnosis of schizophrenia; eating disorders, sleep disorders, sexual disorders, and
obsessive–compulsive disorders were reported at lower rates.
b 50% (n = 337) of the patients reported family history of psychiatric disorders; intellectual disability, anxiety disorders, dementia, obsessive–compulsive disorder, eating dis-
order, and personality disorder were reported at lower rates.
c Related to all patients, including those without relapses or admissions during the speciﬁed period.
d Established in percentages and ranging in the study from 15% to 100%. Governmental classiﬁcation systemwith anchor percentages; 0%means a permanent handicap proof by
objective measures not involving disability; from 1% to 24% corresponds to permanent handicap resulting in amild disability; from 25% to 49% corresponds to permanent handicap
resulting in amoderate disability; from 50% to 70% corresponds to permanent handicap resulting in a severe disability; from 70% onwards corresponds to permanent disability pro-
ducing high severe handicap with a dependent status to carer for daily living activities.
e Total score is in a range from 0 to 20 and subscales from ranging from 0 to 5. Higher scoremeans higher disability. For each subscale few patients showed Functioningwith Help
i.e. Personal Care 6.9% (n = 46), Occupational Functioning 8.4% (n = 56), Familiar Functioning 7% (n = 47), and Broad Social Context Functioning 7.9% (n = 53).
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served in the 1.5 SD cut-off compared to a normal reference distribu-
tion (i.e., 9.06%) except for the test of verbal memory for items (see
Table 2).
Impairment prevalence estimates with 95% CIs for each cognitive
tests were, from low to high, verbal memory (items), 11.7% (95% CI
11.0–12.4%); working memory (Letter-Number Sequencing), 20.9%
(95% CI 20.2–21.6); and verbal memory (units), 24.8% (95% CI
24.1–25.5%). Themost prevalent impairmentswere in executive func-
tion and processing speed (Category Fluency Test and Digit-Symbol
Coding), with Digit-Symbol Coding percentages of 38.1% (95% CI
37.5–38.3%); Category Fluency Test-Animals 68.3% (95% CI67.8–68.8%); and Category Fluency Test-Fruits 85.9% (95% CI
85.6–86.2%). The population-adjusted prevalence was very similar
(results are included as supplementary material, see Supplementary
Table 1).
As expected, marked heterogeneity was observed in overall cog-
nitive performance. Most of the patients had cognitive impairment
in one or two of the assessed cognitive domains i.e. 41% (n = 220
cases) had cognitive impairment in one, and 30.6% (n = 164) had
cognitive impairment in two domains. Impairement for three or
four domains were lower: 12% (n= 67) and 9.3% (n= 50), respec-
tively. A small number of patients had normal performance in all
assessed areas (6%, n= 35).
Table 2
Results obtained from the EPICOG-SCH cognitive battery and prevalence of cognitive impairment.
Raw Score Standardized Score Percentage of patients with Cognitive Impairment
Cognitive Subtest n Mean SD Min Max n Mean SD Min Max Cut off scores for Scalar Scores
≤1 SD (Score ≤ 7) ≤1.5 SD (Score ≤ 5.5) ≤2 SD (Score ≤ 4)
Letter-Number Sequencing (WAIS-III)a 670 8.5 3.9 0 21 647 8.9 3.9 0 19 37.7 20.9 12.8
Digit-Symbol Coding (WAIS-III)a 671 43.6 21.5 0 133 648 6.3 3.4 1 19 63.4 38.1 27.9
Logical Memory (WMS-III-Text A)a
Units 672 10.4 4.6 0 23 641 8.4 3.4 1 19 38.0 24.8 12.2
Issues 672 4.6 1.7 0 7 649 9.4 2.8 2 15 25.4 11.7 6.0
Cut off scores for Centile Scores
Centile_25 Centile_10 Centile_5
Category Fluency Test (total score)b 672 39.4 15.6 0 148 – – – – – – – –
Animals 672 14.0 5.6 0 39 539 3.0 2.6 1 13 85.9 68.3 59.9
Fruits 672 10.0 3.6 0 31 539 1.9 1.7 1 14 97.6 85.9 76.9
Cities–Villagesc 672 15.5 8.1 0 78 – – – – – – – –
SD, Standard Deviation.
Observed percentages of patients showing cognitive impairment for all subtests are higher than the expected percentages in a normal distribution i.e. 15.7% for ≤ 1 SD and 2.3%
for ≤ 2 SD.
When interpreting the estimated prevalences, the similarities and differences between the study sample and normative sample need to be taken into account. In this sense, some
differences on sociodemographic factors were observed: participants on the normative samples for WAIS-III and WMS-III were older than the patients in the study sample
(p = 0.000014 and p = 0.0001 respectively) and also the normative sample was composed of a lower percentage of men than the study sample (p = 0.0001 for both WAIS-III
and WMS-III). Regarding education, patients on the normative sample for WAIS-III had a lower percentage of patients with primary school completed (p b 0.0001) compared to
the study sample that showed a higher level of education. Information about education was not available for WMS-III normative sample.
With regards Category Fluency normative samplewas older (p b0.0001) andwith a higher level of education (pb0.0001). Years of education have a clear impact on theperformance
of this subtest (Buriel et al., 2004).
a Standardized as scalar scores (mean 10 SD 3) (Weschler, 2001).
b Standardized as centile score. Available normative data only for patients aged 20 to 49 years old (Buriel et al., 2004).
c No available normative data in Spain. The category “vegetables”was substitutedwith “cities–villages” due to the issues related to the category “vegetables” in Spanish language,
as noted in past published research (Buriel et al., 2004). The category “cities” is one of the categories included in the Set-Test of Isaacmeasuring category ﬂuency validated in Spain
(Pascual et al., 2000).
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versely andmoderately associatedwith the level of functional disabil-
ity assessed by the WHO DAS-S; higher performance was related to
less disability (see Table 3).
Patients who were actively employed at the time of participation
in the study or who were in training programs performed better on
all tests (see Table 4).
3.3. Cognitive performance and clinical proﬁle
With respect to criterion validity, the relationship between per-
formance on cognitive tests and the patient’s overall clinical statusTable 3
Relationship between clinical impression, disability and cognitive results.
ICG- SCHa WHO-DAS-S Dimension
Cognitive test (N = 672) General
Subscale
Cognitive
Subscale
Personal
Care
Family and
household
Letter-number sequencing-
WAIS-III
−0.33⁎⁎⁎ −0.35⁎⁎⁎ −0.37⁎⁎⁎ −0.30⁎⁎⁎
Digit-symbol coding-WAIS-
III
−0.23⁎⁎⁎ −0.28⁎⁎⁎ −0.31⁎⁎⁎ −0.25⁎⁎⁎
Category Fluency Test (total
score)
– – −0.30⁎⁎⁎ −0.25⁎⁎⁎
Animals −0.19⁎⁎⁎ −0.25⁎⁎⁎ −0.27⁎⁎ −0.23⁎⁎⁎
Fruits −0.20⁎⁎⁎ −0.23⁎⁎⁎ −0.30⁎⁎⁎ −0.22⁎⁎⁎
Cities/Villages – – −0.27⁎⁎⁎ −0.23⁎⁎⁎
Logical Memory*-WMS-III-
Text-A
Units −0.26⁎⁎⁎ −0.29⁎⁎⁎ −0.24⁎⁎⁎ −0.23⁎⁎⁎
Issues −0.21⁎⁎⁎ −0.20⁎⁎⁎ −0.15⁎⁎⁎ −0.19⁎⁎⁎
Statistical Signiﬁcance: ⁎⁎ p b 0.001 ⁎⁎⁎ p b 0.0001.
CGI-SCH-SCH, The Clinical Global Impression-Schizophrenia scale (Haro et al., 2003a,b).
WHO DAS-S World Health Organization Disability Assessment Scale Short Version (Janca et
a Correlation coefﬁcients using standardized scores for cognitive subtests.
b Correlation coefﬁcients using raw scores for cognitive subtests.according to the clinical impression was moderate and statistically
signiﬁcant. Therefore, the more clinically severe patients, according
to the CGI-SCH-Overall severity and Cognitive scales, performed more
poorly on cognitive tests (see Table 5). In both cases, performance
in the working memory domain (Letter-Number Sequencing) had
the highest correlation with the clinical impression of severity as
assessed by the clinician´s CGI-SCH subscale.
For the remaining evaluated clinical aspects, such as negative
symptoms, depressive symptoms and the presence of the Deﬁcit
Syndrome, the results are shown in Figs. 1 and 2 and Table 5. In
all cases, the severity of the associated symptoms showed a statis-
tically signiﬁcant inverse relationship to cognitive performancesb
Occupational
Functioning
Functioning in Broader Social
Context
WHO-DAS-S Total
Score
−0.30⁎⁎⁎ −0.31⁎⁎⁎ −0.39⁎⁎⁎
−0.27⁎⁎⁎ −0.27⁎⁎⁎ −0.33⁎⁎⁎
−0.27⁎⁎⁎ −0.28⁎⁎⁎ −0.33⁎⁎⁎
−0.27⁎⁎⁎ −0.24⁎⁎⁎ −0.31⁎⁎⁎
−0.24⁎⁎⁎ −0.24⁎⁎⁎ −0.29⁎⁎⁎
−0.23⁎⁎⁎ −0.27⁎⁎⁎ −0.30⁎⁎⁎
−0.21⁎⁎⁎ −0.25⁎⁎⁎ −0.28⁎⁎⁎
−0.14⁎⁎⁎ −0.19⁎⁎⁎ −0.21⁎⁎⁎
al., 1996; Sartorius et al., 1986).
Table 4
Results on cognitive tests on EPICOG-SCH battery according to occupational status.
Occupational Statusa
Cognitive Test Active Status
(n = 204)
Non Active Status
(n = 417)
Mean SD Mean SD Sign. 95% IC of Difference
Low High
Letter-number sequencing-WAIS-III 9.3 4.0 8.3 3.9 p = 0.0023⁎⁎ 0.3 1.6
Digit-symbol coding-WAIS-III 49.5 20.1 40.7 20.5 p b 0.0001⁎⁎⁎ 5.4 12.2
Fluency Test (Total) 43.1 16.6 38.3 15.0 p = 0.0014⁎⁎ 2.2 7.4
Animals 15.2 6.0 13.5 5.6 p = 0.022⁎ 0.7 2.7
Fruits 10.7 3.6 9.8 3.5 p = 0.0091⁎⁎ 0.3 1.5
Cities/Villages 17.2 8.8 15.1 7.8 p = 0.0026⁎⁎ 0.8 3.6
Verbal Memory-WMS-III*
Units 11.8 4.6 9.9 4.6 p b 0.0001⁎⁎⁎ 1.1 2.7
Issues 5.1 1.5 4.4 1.7 p b 0.0001⁎⁎⁎ 0.4 1.0
95% IC, Conﬁdence Interval; Statistical Signiﬁcance: *p b 0.05, **p b 0.01,***p b 0.001, ****p b 0.0001.
Patients in an active situation showed better results in all cognitive tests in the EPICOG-SCH battery compared with those in a non-active situation.
a Active Status included active workers, students and patients in charge of housework while non-active included unemployed and retire patients.
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tionship was also true, except in the verbal memory domain,
where patients with depressive symptoms showed similar results
to those with no such current symptoms. Finally, the subgroup of
patients with the Deﬁcit Syndrome performed poorly on all tests
(see Table 5).
The ﬁrst multiple linear regression model was constructed using
only the results of cognitive tests (standardized scores) and ex-
plained 12.13%of the variability of functional disability,with signiﬁcant
coefﬁcients only for the subtests of Letter-Number Sequencing (OR=
−0.32, P b 0.0001) and Category ﬂuency Test-Fruits (OR =−0.35,Table 5
Results on cognitive tests on the EPICOG-SCH battery and functional disability according to
Deﬁcit Syndromea De
Meet
Criteria
(n = 453)
Not Meet
(n = 209)
Pr
(n
Mean SD Mean SD p-value M
Cognitive Tests
Letter-number sequencing-WAIS-IIId 8.3 3.7 10.1 3.9 b0.0001⁎⁎⁎⁎ 8
Digit-symbol coding-WAIS-IIId 6.0 3.3 7 3.3 b0.0002⁎⁎⁎ 6
Category Fluency Test (Total)d 36.9 14.7 44.8 16.3 b0.0001⁎⁎⁎⁎ 38
Animals 13.2 5.6 15.6 5.7 b0.0001⁎⁎⁎⁎ 13
Fruits 9.5 3.5 11.1 3.6 b0.0001⁎⁎⁎⁎ 9
Cities/Villages 14.2 7.5 18.1 8.8 b0.0001⁎⁎⁎⁎ 15
Verbal Memory -WMS-III-Text-Ae
Units 7.9 3.2 9.5 3.6 b0.0001⁎⁎⁎⁎ 8
Issues 9.2 2.8 10.1 2.7 b0.0001⁎⁎⁎⁎ 9
WHO-DAS-S Subscales
Personal Care 1.3 1.1 0.6 0.9 b0.0001⁎⁎⁎⁎ 1
Occupational Functioning 2.8 1.3 1.7 1.3 b0.0001⁎⁎⁎⁎ 2
Family and Household 2.2 1.1 1.4 1.1 b0.0001⁎⁎⁎⁎ 2
Functioning on Broader Social Context 3.0 1.2 1.8 1.2 b0.0001⁎⁎⁎⁎ 2
WHO DAS-S, World Health Organization Disability Scale-Short Version (Janca et al., 1996; S
Statistical Signiﬁcance: *p b 0.05, **p b 0.01,***p b 0.001, ****p b 0.0001.
a According to speciﬁc criteria for Deﬁcit Syndrome (Arango et al., 1998, 2004; Kirkpatric
areas i.e. Personal Care, Chi2 = 54.6915, gl = 5, p b 0.0001; Occupational Functioning. C
p b 0.0001; Functioning in Broader Social Context Chi2 = 125.4340, gl = 5, p b 0.0001).
b According to Depression Subscale of CGI-SCH (Haro et al., 2003a,b). Depressive sympto
Care, Chi2 = 27.2771, gl = 5, p b 0.0001; Occupational Functioning, Chi2 = 22.1539, gl =
ing in Broader Social Context, Chi2 = 29.0690, gl = 5, p b 0.0001).
c Subgroup of patients treated with anticholinergic agents was similar to other patients r
subgroup had a higher percentage of patients at higher severity scores on the ICG-General
d Raw scores.
e Standardized scores.p =0.0006). A second regression model was constructed, by adding
clinical variables such as clinical impression of severity (CGI-SCH) and
course of the disease (as the number of relapses in the previous year,
number of admissions and the time course of the condition) to the
scores of the cognitive tests (standardized). The resultingmodel isolat-
ed four factors that explained 47% of the observed variability of func-
tional disability: CGI-SCH-Overall Severity (OR = 1.34635,
p b 0.0001), CGI-SCH-Negative Symptoms (OR = 0.75540,
p b 0.0001), working memory (Letter-Number Sequencing) (OR =
−0.16442, p = 0.0004), and the time course of the disorder (OR =
0.05083, p = 0.0094).patient’s clinical proﬁle.
pressive Symptomsb Anticholinergic Treatmentc
esent
= 429)
Absent
(n = 238)
Yes
(n = 105)
No
(n = 567)
ean SD Mean SD p-value Mean SD Mean SD p-value
.7 3.9 9.3 3.8 0.0193⁎ 8.2 4.1 9.0 3.8 0.0179⁎
.1 3.3 6.8 3.6 0.0368⁎ 5.9 3.5 6.3 3.3 0.1467
.2 15.9 38.2 15.9 0.0098⁎⁎ 37.0 14.4 39.9 15.8 0.0525
.5 5.8 14.8 5.7 0.0104⁎ 13.5 5.5 14.1 5.8 0.3333
.7 3.6 10.5 3.5 0.0068⁎⁎ 9.6 3.26 10.1 3.6 0.2291
.1 8.5 16.2 7.5 0.0328⁎ 13.9 7.6 15.6 8.2 0.0223⁎
.4 3.5 8.4 3.1 0.5726 ns 7.1 3.4 8.6 3.3 b .0001⁎⁎⁎⁎
.4 2.9 9.6 2.3 0.4159 ns 8.3 2.9 9.7 2.8 b .0001⁎⁎⁎⁎
.2 1.1 0.8 1.0 b0.0001 – – – – –
.6 1.4 2.2 1.5 b0.0002 – – – – –
.0 1.1 1.7 1.2 b0.0003 – – – – –
.7 1.2 2.3 1.4 b0.0001 – – – – –
artorius et al., 1986).
k et al., 2000). Deﬁcit Syndrome was signiﬁcantly related to functional disability in all
hi2 = 102.9530, gl = 5, p b 0.0001; Familiar Functioning, Chi2 = 67.8735, gl = 5,
ms were signiﬁcantly related to functional disability in all areas evaluated i.e. Personal
5, p = 0.0005; Familiar Functioning, Chi2 = 24.7892, gl = 5, p = 0.0002; Function-
egarding socio-demographic variables i.e. age, gender and years of education. This
Subscale (p = 0.0054).
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Fig. 2.Patientswith depressive symptoms (e.g. sadness, depressedmood orhopelessness) showed lowerperformance onCategory Fluency, Letter Sequencing andDigit Coding tests.
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of schizophrenic outpatients studied was associated with both
clinical and cognitive variables and with the evolution of the
disorder; the cognitive domain of working memory showed
the highest relationship to the patient’s overall functional
disability.
4. Discussion
In this study,we describe the cognitive performance of the EPICOG-
SCH battery subtests on a large sample of schizophrenia patients re-
ceiving stable treatment from second-generation antipsychotic drugs.
The lowest performancewas obtained in tests assessing executive func-
tion and speed of information processing, followed by tests of working
memory and verbal memory, where the results obtained were below
the normative reference population. The cognitive impairment with
the higher prevalence (b1.5 SD below the mean) was found for the
executive function domain (between 70 and 80% of the sample ac-
cording to the subtest) and information processing speed, which
had a prevalence of nearly 40%.
However, along with other clinical factors, the domain that had
the highest association with overall patient functional disability was
the working memory.
This result is consistent with previous studies conducted with
clinically stable patients, which reported similar results in working
memory and occupational functioning (Hofer et al., 2005) and be-
tween patients with and without cognitive deﬁcits according to
their state of competitive employment or vocational functioning
using a cut-off of b2 SD (Holthausen et al., 2007). In other studies,
working memory, along with other domains, such as processing
speed and attention, was also associated with functional outcomes
in social and functional skills (Bowie et al., 2008). In addition, in our
study,working memorywas the domain that had the highest correla-
tionwith the clinical criteria of cognitive impairment according to the
CGI-SCH Cognitive Subscale.
Various studies have identiﬁed subtests, such as symbol coding and
ﬂuencies, along with tests that have components such as processing
speed, to be valid and efﬁcient indicators of overall cognitive function-
ing using different patient groups (Hurford et al., 2011; Wong et al.,
2013). With regard to functional outcome, recently Fervaha et al.
(2014) using data from the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study, concluded that the subtests of working
memory and information processing speed (Letter Sequencing and
Digit-Symbol Coding, respectively) were a valid estimate of overall
cognitive status and had a similar relationship to clinical and functional
outcomes, as in this administration of the full EPICOG-SCH battery.
The relationship between overall functional status and the cog-
nitive status of patients has been widely discussed and is not as di-
rect as it was believed to have been in the past. In our study, this
relationship was mediated by other factors. In the sample of pa-
tients studied, patient functioning was related not only to cogni-
tive status and to other clinical factors, such as overall severity
and associated negative symptoms, but also to the course of the
disease as the time of the disorder’s evolution. Our model ex-
plained 47% of the variability in this large sample of clinically sta-
ble patients monitored on an outpatient basis. The relevance of the
time of evolution on cognitive status was highlighted in a meta-
analysis study that included 113 different studies. In this study,
time of evolution of the disease was a large source of variation contrib-
uting to the heterogeneity observed in studies of cognitive impairment
in schizophrenia (Fioravanti et al., 2005, 2012).
The contribution of cognition to patient functional status has been
examined in several studies, with percentages of the explained
variability in functional status accounted for by performance on cog-nitive tests in the range of 10–40% (Velligan et al., 1997); this range is
due to different factors, such as the social context and type of patients
studied. With increasing experience and information on this subject,
understanding the interaction between cognition and the functioning
of patients in the community has becomemore complex (Green, 2007).
With respect to the factors associatedwith cognitive outcome, the
association between negative symptoms and cognitive status has
also been reviewed and described in multiple previous studies
using more speciﬁc tools (Bowie et al., 2008; Harvey et al., 2006b;
Hurford et al., 2011; Keefe et al., 2006; Milev et al., 2005; Palmer
et al., 2009; Velligan et al., 2004; Villalta-Gil et al., 2006), where neg-
ative symptoms have been associated with functional areas of work,
education and social functioning (Shamsi et al., 2011; Lin et al.,
2013). In contrast, the inﬂuence of depressive symptoms on cogni-
tion in schizophrenia has produced conﬂicting results in the past
(Stip and Mancini-Marie, 2004; Holthausen et al., 2007). In our
study, although the presence of symptoms of depression did not
seem to affect performance in verbal memory-immediate recall, it
did negatively inﬂuence performance in the remaining tests, which
conﬁrmedpreviousﬁndings that this factor could have a different im-
pact depending on the domain being assessed (Bowie et al., 2008). In
the subgroup with depressive symptoms, women were
predominating and, although their ages and educational level were
similar to the cases without depressive symptoms, they obtained
higher clinical severity scores on the CGI-SCH scale, which may par-
tially explain the observed results.
Finally, patients who met the criteria for the Deﬁcit Syndrome
(Arango et al., 1998, 2004; Kirkpatrick et al., 2000) obtained lower
scores on the cognitive tests compared to the scores of patients who
did not meet the criteria. This group consisted of older patients with
less education and greater clinical severity assessed by the CGI-SCH
overall severity scale, factors that in turn may have inﬂuenced cogni-
tive outcomes. These results should be viewed with caution due to
the limitations involved in evaluating symptoms using clinical impres-
sion scales. Future studies should include speciﬁc validated scales in
schizophrenia and train raters on the administration of tests.
With respect to limitations, it should be noted that the patients
studied were clinically stable and had mild to moderate degrees of se-
verity, thus compromising the external validity of the results in other
populations of outpatients with more severe schizophrenia. In addi-
tion, cross-sectional studies do not allow for the establishment of caus-
al relationships among the factors studied, and prospective studies are
required to conﬁrm any causal links. Also, due to time constrains at
clinical settings, the number of subtests included in the resulting bat-
tery is not comprehensive enough to provide a complete picture of pa-
tient cognitive status and this is important to take into account when
considering our results. Lastly, for this project raters were not trained
to administer the cognitive or the clinical tests. Raters were requested
to have demonstrable experience performing cognitive testing and a
telephonic trainingwas offered in this context, however few investiga-
tors used this resource. Although no major ﬁndings were observed
with regards to quality of registered data, the lack of training on the ad-
ministration of the tests has compromised the quality of test adminis-
tration and in turn, the results presented in this paper.
At the time of the study, we found that little attention has been
paid to the cognitive state of patients in Spain due to the low percent-
age of cases that had received cognitive assessments. Although cogni-
tive deﬁcit is recognized in schizophrenia, a recent survey of
psychiatrists in Europe, Asia and the US also revealed that only 12%
of psychiatrists use appropriate tests for cognitive assessments, and
in general, population-normative data are not used to interpret re-
sults (Belgaied et al., 2014).
An individualized assessment of cognitive status, using objective
and validated cognitive tests that have normative data available from
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propriate in clinical practices with outpatients. This assessment would
provide a good estimate of the cognitive state of patients compared to
that of the general population andwould inform or advise the patients
and their families about their potential functional development in daily
life. The assessment would also allow for the observation of the evolu-
tion and ﬂuctuation of cognitive states throughout the course of the
disease based on the different therapeutic interventions and rehabilita-
tion programs.
Monitoring the ability of working memory and speed of informa-
tion processing becomes particularly relevant in our study because
of their potential impact on functional capacity and changes in dos-
age of drugs, adjustments of antipsychotic drugs or simultaneous
medication (anticholinergic agents, etc.).
The EPICOG-SCH cognitive battery subtests allowedus todifferen-
tiate among patients according to their overall functional status, their
employment status and ongoing training activities. For schizophre-
nia, short batteries of tests have been shown to have a good corre-
lation with the more thorough long batteries of tests (between
0.56 and 0.77) (Wong et al., 2013). This level of efﬁciency is signif-
icant in clinical situations in which available time for assessment is
limited. The EPICOG-SCH battery, which includes four domains
relevant to functional outcome, may be a good alternative tool
for use in routine clinical practice. This methodology would re-
quire completing its psychometric study, analyzing the sensitivity
to clinical and pharmacological changes and providing alternative
versions of each subtest for repeated administrations.
This study proposes a brief cognitive assessment battery that de-
termines patient cognitive status. The EPICOG-SCH battery, in its ex-
perimental version, has proven to be related to functional outcome
variables, such as overall disability and occupational status; further-
more, it has proven to be sensitive to clinical aspects of the disease
that are related to cognition.
This study constitutes the ﬁrst step toward the construction and
validation of a cognitive battery for clinical practice in schizophrenia
with speciﬁc purposes. The battery will consist of widely known tests
with available normative data, which will allow for use in different
health care settings in different countries. This battery will be able
to be administered in a limited amount of time, will be easy to inter-
pret, and will require only limited resources. The results of the test
battery will provide a good estimate of a patient’s cognitive state rel-
ative to the general population and will be designed to inform or ad-
vise patients and their families about potential functional
development for performing activities of daily life.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.scog.2015.03.002.
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